Efficacy of venetoclax combined with hypomethylating agents in the treatment of patients newly diagnosed with core binding factor acute myeloid leukemia
10.3760/cma.j.cn121090-20241209-00546
- VernacularTitle:维奈克拉联合去甲基化药物在不能耐受强化诱导治疗的初治核心结合因子相关急性髓系白血病患者中的疗效分析
- Author:
Siyi HAN
1
;
Xiaoyan XU
1
;
Meng ZHOU
1
;
Haixia ZHOU
1
;
Depei WU
1
;
Yue HAN
1
Author Information
1. 苏州大学第一附属医院血液科，苏州 215006
- Publication Type:Journal Article
- Keywords:
Core-binding factor leukemia;
Venetoclax;
Hypomethylating agents
- From:
Chinese Journal of Hematology
2025;46(8):738-742
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy of venetoclax combined with hypomethylating agents (Ven-HMA), in patients with core binding factor acute myeloid leukemia (CBF-AML) intolerant to intensive induction therapy.Methods:This study retrospectively analyzed patients newly diagnosed with CBF-AML who were aged <60 years and who received Ven-HMA as induction therapy at the Department of Hematology, the First Affiliated Hospital of Soochow University, between January 2020 and June 2023. Baseline characteristics and treatment responses of the patients were collected.Results:A total of 70 treatment-na?ve patients receiving Ven-HMA induction therapy were enrolled, of which 38 were men and 32 women [median age: 43 (34 - 55) years]. Of the 70 patients, 44 (62.9%) achieved complete remission (CR) /CR with incomplete hematologic recovery (CRi), 16 (22.9%) achieved partial remission, and 10 (14.2%) exhibited no response after one induction cycle. Among the 32 t (8;21) -positive patients with AML, only 8 (25.0%) achieved CR/CRi, of whom 3 (37.5%) remained measurable residual disease (MRD) -positive; among the 38 inv (16) -positive patients, 36 (94.7%) achieved CR/Cri, of whom 12 (33.3%) remained MRD-positive. Patients harboring the CBFβ::MYH11 fusion gene showed significantly higher response rates to Ven-HMA induction than those with the RUNX1:: RUNX1T1 fusion gene ( P<0.01) . Conclusion:Ven-HMA represents a novel therapeutic strategy that exhibits significant efficacy in inv (16) -positive patients; however, it demonstrates relatively lower remission rates in t (8; 21) -positive patients.
